Filling a need
TDL Innovations, LLC was founded in 2014 to develop medical technologies to treat important medical conditions. We bring together exceptional scientists and experienced leadership around our shared mission to deliver new therapies to cancer patients.
Our technology driven life-saving innovations will restore and improve the quality of life for patients with cancer.
Each year about 200,000 people develop a devastating complication of cancer termed a Malignant Pleural Effusion ("MPE"). MPE is a build-up of fluid between the lung and the chest wall. As the fluid accumulates it compresses the lung preventing it from fully expanding, which results in severe shortness of breath and other symptoms. Typically, MPE occurs as a late-stage complication of cancer and frequently impacts the quality of life. The current therapeutic options for MPE are suboptimal as they are not always successful and can be invasive, prone to complications and burdensome to the patient.
Talc pleurodesis is a common treatment strategy for MPE but is not always successful. One factor reducing its effectiveness is thought to be due to poor dispersion of the active agent throughout the chest.
TDLI is developing a novel treatment to improve the delivery of talc. This technology driven solution can potentially improve a patients quality of life, and address unmet needs. Pre-clinical research has shown that administering the active agent through a foam delivery platform (Talc Foam) significantly improved pleurodesis, enhanced survival rates (compared to the Talc slurry), and reduced loss of right lung volume.